Suggested remit: To appraise the clinical and cost effectiveness of imlifidase within its marketing authorisation for desensitisation treatment before kidney transplantation in highly sensitised people with chronic kidney disease.
Status Proposed
Process STA 2018
ID number 1672

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
17 January 2020 (10:00) Scoping workshop (Manchester)
14 November 2019 - 12 December 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance